AEON Biopharma

AEON Biopharma, Inc. announced a public offering of units including Common Stock and warrants, with Aegis Capital Corp. managing the offering. Proceeds will fund corporate needs. AEON focuses on developing ABP-450, a botulinum toxin complex for medical conditions, with exclusive rights in several territories.

The Cervical Dystonia therapeutics market is evolving due to advancements, with emerging therapies like Daxibotulinumtoxin A and ABP-450. The 'Cervical Dystonia Pipeline Insight, 2024' report by DelveInsight provides a comprehensive evaluation of pipeline products, covering mechanisms of action, clinical studies, and NDA approvals. The report highlights key companies and therapies in the market, including Ipsen, Allerga, Medytox, Addex Therapeutics, and Revance Therapeutics.

AEON Biopharma announced positive FDA Biosimilar Advisory Meeting outcome for ABP-450 as a BOTOX® biosimilar, aligning on the 351(k) regulatory pathway. Comparative analytical studies start Q4 2024, with a BPD Type 2 meeting planned for 2025. AEON aims to bring prabotulinumtoxinA to the U.S. market for all BOTOX's approved and future therapeutic indications under a single approval, anticipating a Phase 3 program to compare ABP-450 with BOTOX®.

A study in The BMJ reviews drug interventions for migraine, emphasizing triptans' efficacy and need for wider access. Experts highlight the importance of comparing new drugs to current treatments and involving patients in research design. The study also notes limitations in trial heterogeneity and individual patient insights.